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Essentials
• Loss of fibrinogen in zebrafish has been previously
shown to result in adult onset hemorrhage
• Hemostatic defects were discovered in early fga/
embryos but well tolerated until adulthood
• Afibrinogenemia and thrombocytopenia results in syn-
thetic lethality in zebrafish.
• Testing human FGA variants of uncertain significance
in zebrafish identified causative mutations
Summary. Background: Mutations in the alpha chain of
fibrinogen (FGA), such as deficiencies in other fibrinogen
subunits, lead to rare inherited autosomal recessive hemo-
static disorders. These range from asymptomatic to catas-
trophic life-threatening bleeds and the molecular basis of
inherited fibrinogen deficiencies is only partially under-
stood. Zinc finger nucleases have been used to produce
mutations in zebrafish fga, resulting in overt adult-onset
hemorrhage and reduced survival. Objectives: To deter-
mine the age of onset of hemostatic defects in afibrino-
genemic zebrafish and model human fibrinogen
deficiencies. Methods: TALEN genome editing (transcrip-
tion activator-like effector nucleases) was used to generate
a zebrafish fga mutant. Hemostatic defects were assessed
through survival, gross anatomical and histological obser-
vation and laser-induced endothelial injury. Human FGA
variants with unknown pathologies were engineered into
the orthologous positions in zebrafish fga. Results: Loss
of Fga decreased survival and resulted in synthetic lethal-
ity when combined with thrombocytopenia. Zebrafish fga
mutants exhibit a severe hemostatic defect by 3 days of
life, but without visible hemorrhage. Induced thrombus
formation through venous endothelial injury was com-
pletely absent in mutant embryos and larvae. This hemo-
static defect was restored by microinjection of wild-type
fga cDNA plasmid or purified human fibrinogen. This
system was used to determine whether unknown human
variants were pathological by engineering them into
fga. Conclusions: These studies confirm that loss of fib-
rinogen in zebrafish results in the absence of hemostasis
from the embryonic period through adulthood. When
combined with thrombocytopenia, zebrafish exhibit syn-
thetic lethality, demonstrating that thrombocytes are nec-
essary for survival in response to hemorrhage.
Keywords: fibrinogen; genome editing; hemostasis;
thrombocytopenia; zebrafish.
Introduction
Hemostasis is a critical requirement for maintaining
blood circulation and upon injury a cascade of enzymatic
reactions is initiated. Platelets adhere to the site of injury
and are activated, forming the primary plug, after which
coagulation factors trigger a burst of thrombin produc-
tion, driving the conversion of soluble fibrinogen to an
insoluble fibrin clot. The regulation of coagulation factor
activation and inhibition provides checks and balances
that assure proper clot formation and eventual dissolu-
tion. Aberrations to these pathways result in both
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bleeding or clotting disorders, which contribute to hemor-
rhage, ischemia, surgical complications and even death
[1].
Fibrinogen is a liver-derived hexameric glycoprotein
encoded by paralogous genes FGA, FGB and FGG (cod-
ing for Aa, Bb and c chains, respectively) on human chro-
mosome 4 (4q31.3–4q32.1) [2–4]. In the presence of
thrombin, fibrinopeptides (A and B) are removed, leaving
fibrin monomers, which are stabilized by FXIII cross-
linking [3,5–8], driving insoluble clot formation. Muta-
tions in FGA, FGB or FGG can all affect the synthesis,
assembly, intracellular processing, stability or secretion of
fibrinogen. Congenital deficiency of fibrinogen, either
quantitatively (hypofibrinogenemia and afibrinogenemia)
or qualitatively (dysfibrinogenemia), is an inherited auto-
somal bleeding disorder with heterogeneous penetrance,
although the latter has been shown to result in thrombo-
sis in some cases [9]. Hemorrhaging can occur in various
tissues such as skin, soft tissues, muscles, joints, the gas-
trointestinal tract or genitourinary tract, with intracranial
bleeding being a major cause of death [4,10–12]. Afibrino-
genemia is estimated to occur in 1 per 1 000 000 individu-
als [11,13] and cumulatively congenital fibrinogen
disorders are thought to make up 8% of all rare coagula-
tion disorders [14]. A majority of diagnosed dysfibrino-
genemia and afibrinogenemia cases have been attributed
to mutations and modifications within the FGA sub-chain
[15].
Current therapeutic strategies for congenital fibrinogen
deficiency include replacement with fresh-frozen plasma,
cryoprecipitate or plasma-derived fibrinogen concentrate.
Unfortunately, these treatments have been linked to nega-
tive outcomes, including transfusion-associated complica-
tions, off-target effects on related plasma proteins and
failed virus inactivation [10,16–18]. Consequently,
increased risk and diminished treatment efficiency result
in reduced clinical administration [19].
To improve treatments for fibrinogen-related disorders,
further interrogation of the disease mechanisms in physio-
logically relevant model systems is required. In recent
years, zebrafish (Danio rerio) has become an increasingly
popular model for studying blood pathologies because of
high genetic and physiologic homology to humans. Zebra-
fish are economical, easy to maintain and manipulate,
and undergo rapid, external development as transparent
embryos or larvae, making them amenable to hemostatic
assays. We and others have demonstrated a high degree
of conservation of the coagulation cascade between zebra-
fish and humans, identifying homologs for nearly all
major factors [20–25], with strong data implicating
mononuclear thrombocytes as functional equivalents to
platelets [26,27]. However, thrombocytes have not been
proven to be required for survival in response to hemor-
rhage. Recent advancements in genome editing technolo-
gies (e.g. transcription activator-like effector nucleases
[TALENs] and clustered regularly interspaced short
palindromic repeats [CRISPR]) have enabled the assess-
ment of both individual and multigene knockouts to
interrogate the genetic underpinnings of bleeding and
clotting phenotypes [28–30].
We have previously shown that antisense morpholino-
mediated knockdown of zebrafish fibrinogen chains
results in frequent intracranial and intramuscular hemor-
rhage at 3 days post-fertilization (dpf) [31]. However, this
was not observed in a zinc finger nuclease (ZFN)-
mediated knockout of fga [28]. Instead, mutant fish sur-
vived into adulthood but were found to be underrepre-
sented at 4–5 months of age, with the data suggesting
~40% survival. In this study we used TALEN-mediated
genome editing to generate a transmissible mutation in
fga similar to and recapitulating the phenotypes of the
ZFN mutant. These include survival into adulthood with
no gross larval bleeding, but eventual adult lethality due
to hemorrhage in various tissues. Despite a lack of overt
bleeding, hemostasis was defective as early as 3 dpf.
Interestingly, we were able to reverse the hemostatic
defect after treatment with an antifibrinolytic compound.
We also showed that fga/ fish could be used to discern
human FGA variants that abrogate fibrinogen function.
Finally, loss of the transcription factor Nfe2 results in
severe thrombocytopenia in adult zebrafish [32], similar to
mice [33–35]. Combined deficiency of Fga and Nfe2
results in synthetic adult lethality, which we believe is the
first evidence indicating that thrombocytes are required
in vivo for prevention of hemorrhage and hemostasis-
related survival.
Methods
Zebrafish lines and maintenance
Experiments were performed using AB9TL F1 hybrid
background zebrafish. Embryos derived from natural
spawning were raised at 28.5 °C and developmental stages
(embryo, larva, juvenile and adult [30]) were determined
using age (hours post-fertilization [hpf] or dpf) and mor-
phological characteristics [36]. Animal care and usage
were in accordance with animal care guidelines approved
by the University of Michigan Institutional Animal Care
and Use Committee.
TALEN-induced mutagenesis of coagulation factors in
zebrafish
TALEN-mediated genome editing was used to generate
mutations in exon 2 of zebrafish fga at the target sequence
CTTCAAGGCACAAGAC. Engineered TALENs were
injected into one-cell-stage zebrafish embryos [30,37],
raised to adulthood, and crossed with AB9TL wild-type
fish to confirm germline transmission. The resulting fga
mutants were used for further studies. nfe2 mutants were
previously generated using TALENs [32].
© 2019 International Society on Thrombosis and Haemostasis
608 Z. Hu et al
Genotyping
Zebrafish were anesthetized in tricaine (0.16 mg mL1, Wes-
tern Chemical, Ferndale, WA, USA) and fin biopsies were
obtained [38,39] or fish were humanely killed in high-dose tri-
caine (1.6 mg mL1) followed by DNA preparation. Tissue
was lysed in buffer (10 mM Tris-Cl, pH 8.0; 2 mM EDTA,
2% Triton X-100 and 100 lg mL1 proteinase K) at 55 °C
overnight [29]. Samples were heated to 95 °C for 5 min to
inactivate proteinase K, followed by PCR (primers in
Table S1). PCR products were resolved using agarose gel
electrophoresis or a Qiaxcel capillary electrophoresis system
(Qiagen, Hilden, Germany).
Laser-induced endothelial injury
Laser-induced thrombi were generated after injury of the
endothelium of the posterior cardinal vein (PCV) of larvae
as previously described [40–42]. In brief, zebrafish larvae
were anesthetized at 3 dpf, embedded in agarose (0.8%),
and the endothelium was ablated with a laser at the fifth
somite distal to the anal pore (Olympus IX71 and Micro-
Point Pulsed Laser System, Andor Technology, Belfast,
UK). Time to occlusion was recorded up to 2 min, fol-
lowed by removal of larvae from agarose and subsequent
genotyping.
e-aminocaproic acid treatment
Mutant offspring were derived from fga+/ and fga/
intercrosses. At 24 hpf, embryos were treated with
100 mM e-aminocaproic acid [29,30]. At 3 dpf, laser
injury and genotyping were performed.
Construction and microinjection of expression vectors
Expression constructs and primers used to generate them
are listed in Supplemental Tables S1 and S2. Constructs
were made on the pubi:p2A-EGFP backbone [30] with
wild-type and mutant human and zebrafish fga cDNAs
under control of the zebrafish ubiquitin (ubi) promoter
[43], with bicistronic expression of egfp using the 2A self-
cleaving peptide. Mutations were generated using site-
directed mutagenesis [44], verified by restriction digestion
and sequencing (primers in Table S1), and injected into
one-cell-stage embryos. Mutations are numbered accord-
ing to the human amino acids.
Retro-orbital fibrinogen infusions
Larvae were anesthetized with tricaine at 3 dpf and
placed upon an agarose mold for infusions as previously
described [29]. In brief, human fibrinogen (Sigma, St.
Louis, MO, USA) or bovine serum albumin as a control
(BSA, Sigma) were dissolved in 0.9% NaCl to a final con-
centration of 25 mg mL1 and 2 nL were infused into the
retro-orbital space. Larvae were allowed to recover in sys-
tem water for 1 h before undergoing laser injury and
genotyping.
Quantitative (qPCR) and qualitative PCR analysis
Zebrafish embryos and larvae were homogenized with a 21-
gauge needle in lysis buffer. Total RNA was isolated with the
PureLink RNAMini Kit (Life Technologies, Carlsbad, CA,
USA) or RNeasy Mini Kit (Qiagen) according to the manu-
facturer’s protocols. Total RNA was treated with DNase I
(Invitrogen, Carlsbad, CA, USA) and used for first-strand
cDNA synthesis with oligo (dT)12-18 primers using Super-
script-II (Invitrogen). The cDNA was used for RT-PCR
(Eppendorf MasterCycler) and qPCR (Bio-Rad, iCycler,
Hercules, CA, USA) reactions (primers in Table S1). qPCR
data were analyzed as previously described [45]. Qualitative
PCR analysis was also performed on cDNA derived from
5 dpf larva.
Blood collection and western blot analysis
Adult zebrafish blood was collected and western analysis
performed as described [29,46,47]. Briefly, blood was col-
lected into EDTA-coated microcapillaries (Thermo-
Fisher). One microliter of pooled plasma (at least two fish
per genotype) in buffer with b-mercaptoethanol was
resolved on a 4–20% SDS-PAGE gel (Bio-Rad) and
transferred to nitrocellulose (Bio-Rad). Membranes were
probed with zebrafish anti-fibrinogen antibody, followed
by HRP-conjugated secondary antibody (Santa Cruz,
Dallas, TX, USA), then developed with chemiluminescent
substrate (Super Signal West Femto; ThermoFisher, Wal-
tham, MA, USA) and analyzed on a FluorCheM system
(Protein Simple, San Jose, CA, USA).
Histological examination and o-dianisidine staining
Zebrafish from fga+/ in-crosses were fixed with 4% PFA/
PBST at 4 °C overnight, embedded in paraffin, sectioned
at 4–5 lm, and stained with hematoxylin and eosin (H&E).
Embryos from fga+/ in-crosses were stained at 7 dpf for
hemoglobin with o-dianisidine as previously described
[48,49]. Images were collected on a Leica MZFL III stereo-
scope or Olympus BX51 and recorded using an Olympus
DP70 digital camera.
Assessment of human FGA variants
Variants in human FGA were identified from patients
manifesting with hemorrhage and hypofibrinogenemia as
documented in the Human Fibrinogen Database [50] and
other sources [51]. These were engineered into the orthol-
ogous positions of zebrafish wild-type fga cDNA con-
structs under the control of the ubi promoter (Table S2)
and injected into one-cell-stage mutant offspring
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from fga+/ to fga/ intercrosses, followed by laser
injury at 3 dpf.
Statistical analysis
Statistical analysis was performed using Mann–Whitney U or
two-tailed Student t-tests. Survival was evaluated by log-rank
(Mantel-Cox) testing for significance. Charts and survival
curves were generated using Prism (GraphPad Software, San
Diego, CA, USA).
Results
Targeted mutagenesis of fga using TALENs results in a null allele
Mutations in human FGA result in inherited hypofibrino-
genemia with variable manifestations in humans [1,12,15].
We inactivated the zebrafish fga gene by TALEN-
mediated genome editing in the second exon of fga
(Fig. 1A). A mutant line was identified with a net 26-
nucleotide insertion, resulting in a frameshift and prema-
ture stop codon (Fig. 1B). Frameshifts often result in loss
of expression due to nonsense-mediated decay [29,30] and
we tested this possibility using qPCR. We found that tran-
scription of fga mRNA in 3-day-old fga/ larvae was
nearly undetectable compared to fga+/+, and fga+/ sib-
lings were reduced by ~40% (P = 0.0001 and P < 0.05,
respectively, Fig. 1C). A qualitative assessment of cDNA
isolated from fga/ embryos showed no detectable
fga+/+ expression remaining in mutants (Fig. 1D), and
no residual Fga was observed in plasma isolated from
fga/ adult fish (Fig. 1E). Furthermore, qPCR data indi-
cate that relative transcription levels of other coagulation
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Fig. 1. Generation of a null allele in fga using genome editing with transcription activator-like effector nucleases (TALENs). (A) Schematic of
TALENs targeting exon 2 of fga, located on zebrafish chromosome 1. (B) cDNA sequencing reveals a 26 base pair insertion in fga (indicated by
red box), which generates a frameshift mutation and subsequent nonsense mutation, resulting in truncation. (C) Transcription of fga is remarkably
reduced in fga/ mutants when compared to fga+/+ and/or fga+/ siblings, as evaluated by qPCR (n = 25 larvae per genotype at 3 days post
fertilization (dpf), P = 0.0001 and P < 0.05, respectively, unpaired two-tailed Student’s t-test). (D) Qualitative PCR of cDNA isolated from
fga/ embryos reveals that there is no detectable fga+/+ transcript. (E) Western blot analysis shows no residual Fga present in plasma isolated
and pooled from adult fga/ mutants, in contrast to fga+/+ and fga+/ control siblings. Chr1, chromosome 1; C-term, C-terminal domain; DBD,
DNA-binding domain; Fok I, Fok I nuclease; NLS, nuclear localization signal; N-term, N-terminal domain.
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III (at3), are also significantly reduced in fga/ larvae
(P < 0.05, Fig. S1).
fga mutant survival drops off as fish reach breeding age and
is exacerbated by loss of Nfe2
Targeted mutation of FGA in mice results in a risk of fatal
abdominal hemorrhage, but overall survival is variable
and dependent on genetic background [52]. ZFN-gener-
ated fish mutants produced on a pure AB background
demonstrate ~40% survival at 4–5 months of age [28]. We
tracked the survival of our fga/ mutants and their fga+/
siblings daily. fga/ mutant survival was progressively
reduced compared to the fga+/ siblings over the first year
of life (Fig. 2A; P < 0.0001). Loss of fga in zebrafish did
not manifest in lethality until fga/ mutants approached
breeding age. All fga/ fish were alive at 45 dpf (Fig. 2A),
but survival declined to 90% at 60 dpf and to 40% shortly
after 1 year of age.
In mammals Nfe2 is required for megakaryocyte matu-
ration and platelet formation [33–35], and zebrafish lack-
ing Nfe2 have severe thrombocytopenia with normal
survival [32]. Knockout mice deficient in fibrinogen or
Nfe2 have severe hemostatic defects, with variable survival
into adulthood. Combined deficiency results in death
within 48–72 h after birth [53]. We intercrossed fga and
nfe2 mutant fish and found that loss of both Fga and
Nfe2 resulted in synthetic lethality by 1 year of age
(Fig. 2B; P < 0.0001).
Mutation in zebrafish fga leads to hemorrhage in multiple
tissues
In contrast to other coagulation protein deficiencies
[29,30], loss of fga results in a relatively mild hemorrhagic
phenotype in zebrafish. As seen previously [28], we also
did not detect grossly visible bleeding by o-dianisidine
staining in fga/ larval mutants (data not shown). At 41
dpf juvenile fga/ and fga+/+ siblings were randomly
selected for histological analyses. In homozygous
mutants, 64% manifested with mild or moderate bleeds in
various tissues, including brain, jaw, muscle, fin and
abdomen (Fig. 3A). In addition to previously observed
bleeding in the eyes, brain and abdominal cavity [28],
massive hemorrhage was observed in muscle and mild
bleeding in the jaw, mouth and fins (Fig. 3A). Hemor-
rhaging in the brain progressively worsened by 47 dpf
(Fig. 3B) and was occasionally accompanied by ocular
bleeds. Death was typically preceded by severe intracra-
nial hemorrhage.
The hemostatic defect of fibrinogen deficiency manifests in
the embryonic period
Previously, fga was targeted using ZFNs, resulting in overt
hemorrhage and reduced survival [28]. To address whether
this affects intravascular physiologic hemostasis, we mea-
sured the time to occlusion after laser-induced endothelial
injury of the PCV. Normally, venous thrombus formation
under these conditions occludes the vessel within 2 min-
utes, but this did not occur in fga/ larvae (P < 0.0001,
Fig. 4A). To rescue the hemostatic defect and confirm that
it was due to loss of Fga, we injected a Tol2-mediated zeb-
rafish fga cDNA expression plasmid into one-cell-stage
fga+/ in-cross offspring. At 3 dpf, over 50% of the
injected fga/ larvae displayed PCV occlusion times simi-
lar to their injected and uninjected fga+/+ and fga+/ sib-
lings, which was significantly different to the uninjected
homozygous mutants (P < 0.05 by Mann–Whitney U-test,
Fig. 4B).
We previously demonstrated that loss of At3 in larvae
results in a consumptive coagulopathy that is rescued by
infusion of human fibrinogen [29]. To determine whether
100
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Fig. 2. fga/ mutants demonstrate synthetic lethality with loss of
nfe2. (A) Offspring derived from fga+/ and fga/ intercrosses
were genotyped at 3 days post-fertilization (dpf) and examined
daily. Compared to heterozygous siblings (n = 29), homozygous
mutants (n = 20) exhibit a significant decrease in survival over
time (P < 0.0001 by log-rank testing). (B) Offspring derived from
fga+/; nfe2+/ intercrosses were genotyped at 86 dpf and tracked
for survival. Combined loss of fga and nfe2 results in complete
synthetic lethality by 1 year of age (P < 0.0001 by log-rank
testing).
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human fibrinogen could replace zebrafish fibrinogen, we
infused human fibrinogen concentrate into fga/ larvae.
Approximately half of the infused fga/ mutants showed
significantly shorter occlusion times in comparison with
non-infused fga/ siblings (P < 0.05, Fig. 4C). Together,
our findings confirm that the fga mutation leads to an
intravascular hemostatic defect, similar to that seen in
mouse and human pathologies, which can be reversed by
transient expression of wild-type fga cDNA or infusion of
human fibrinogen protein.
Inhibition of fibrinolysis alleviates the fga/ hemostatic
defect
Fibrinolysis inhibitors are believed to function through
stabilization of the fibrin clot. However, we previously
showed that e-aminocaproic acid can reverse the hemo-
static defect in our model of consumptive coagulopathy,
which is characterized by hypofibrinogenemia [29]. At 24
hpf, fga/ mutants were incubated in e-aminocaproic
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Fig. 3. fga/ mutants develop spontaneous hemorrhage in multiple tissues. (A) Fish were fixed, sectioned, and stained with hematoxylin and
eosin, demonstrating that fga/ mutants (n = 11) develop mild bleeding in the brain and jaw/mouth, but severe bleeding within the abdomen
and abdominal musculature by 41 days post-fertilization (dpf) (compared to wild-type siblings, n = 3). Insets show magnified regions of inter-
est with sites of hemorrhage, as do arrows. (B) Severe bleeds identified in the forebrain (fb), midbrain (mb) and hindbrain (hb) in viable fga/
mutant fish at 47 dpf, in contrast with wild-type siblings. Arrows indicate sites of bleeding. Anterior is towards the left and dorsal is at the
top. Scale bar: 100 lm.
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control fga/ larvae were able to occlude within 2 min-
utes of injury. In contrast, 33% of e-aminocaproic acid-
treated fga/ larvae occluded within 60 s of laser-
induced injury (P = 0.0003, Fig. 5).
Evaluation of human FGA variants in fga-deficient zebrafish
helps link genetic causation to pathology in vivo
We previously showed that we can use zebrafish as an
in vivo system for the identification of the causative muta-
tions in coagulation disorders [29,30]. Because zebrafish
Fga deficiency closely parallels human pathology, human
FGA variants, including C55G, C64Y, Y809C (Human
Fibrinogen Database) [50,54,55] and M1V [51], were
assessed in fga/ zebrafish. These variants have been asso-
ciated with hemorrhage in human populations (Table 1);
however, they have not been functionally validated in vivo.
A multispecies alignment of humans, mice, chickens and
zebrafish demonstrates conservation of these amino acids
across all species. To evaluate each variant’s ability to res-
cue the hemostatic defect in fga mutants, a series of zebra-
fish fga cDNA constructs were generated to express the
variants at positions orthologous to the human FGA muta-
tions (Table S2). Plasmids were injected into one-cell-stage
mutant offspring and subjected to laser-induced endothelial
injury followed by genotyping. M1V and Y809C were not
able to reverse the occlusion defects of fga/ mutant. In
contrast, C55G and C64Y were able to rescue the mutant
hemostatic defect (Fig. 6). By assessing known human gene
variants in fga mutant zebrafish, gene regions that convey
phenotypic deficiencies can be identified, shedding light on
the mechanistic cause of pathologies.
Discussion
We have produced a mutation in exon 2 of the fga gene
in zebrafish using TALENs in a nearly identical location
to that of the three mutant fga lines generated using
ZFNs. The TALENs and ZFN mutations overlap with
differences of eight base pairs or less [28]. In the previous
report, the authors identified spontaneous hemorrhage in
adult fish, but examination of 3 and 5 dpf larvae found
no evidence of bleeding [28]. This suggested the possibil-
ity that hemostasis in early development does not require
the presence of fibrinogen. However, we have previously
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Fig. 4. Laser-mediated injury of the vascular endothelium reveals a
hemostatic defect in fga mutant zebrafish. (A–C) Hemostasis was
evaluated by measuring time to occlusion up to 120 s after laser-
induced endothelial injury of the posterior cardinal vein (PCV) in
3 days post-fertilization (dpf) larvae. Time to occlusion was signifi-
cantly prolonged in fga/ (n = 50) larvae in comparison with fga+/+
(n = 10) and fga+/ (n = 50) siblings (P < 0.0001) (A). Injection of
wild-type fga cDNA into the offspring of fga+/ in-crosses rescued the
hemostatic defect in fga/ compared to uninjected fga/ counterparts
(n = 19–23 per genotype, P < 0.05). Hemostasis in injected fga+/+ and
fga+/ was unaffected compared to uninjected fga+/+ and fga+/
(n = 6–33 per genotype) (B). (C) Retro-orbital infusion of human
fibrinogen into 3-dpf mutant larvae (n = 49) rescued time to occlusion
compared to bovine serum albumin (BSA)-infused fga/ siblings
(n = 21, P < 0.05). P-values determined by the Mann–Whitney U-test.
Horizontal bars represent the median time to occlusion. ns, not
significant.
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demonstrated that induced larval venous thrombi are fib-
rin rich [31], suggesting an important role in embryonic
hemostasis. In this study our endothelial injury experi-
ments confirm that fibrinogen is indeed required for
induced thrombus formation, consistent with our previ-
ous studies of F10 deficiency, as well as observed
hypofibrinogenemia in At3-deficient fish [29,30]. In all
three mutants (fga, f10 and at3), embryonic/larval zebra-
fish tolerate severe coagulopathies into early adulthood
before succumbing, although death occurs at a much
later time-point in the fga mutants. Fish et al. [28] found
~40% survival of homozygous mutants at 4–5 months of
age, whereas at a similar age we recovered 80%, with
40% remaining around 1 year of age. These differences
are likely to be caused by variations in housing or aqua-
culture systems and/or genetic background, because the
prior mutant was generated on a pure AB background
whereas we used an AB9TL hybrid. Similar survival
variations have been observed with targeted mutation of
Fga in mice, which exhibit variable timing of fatal
abdominal hemorrhage depending on the genetic back-
ground. At 2 months of age, 91% of C57BL/6J mice, but
only 57% of the mixed 129/CF-1 background, were
found to be alive [52]. The fish fga mutant data are in
sharp contrast to F10 deficiency, which resulted in death
beginning as early as 1 month of age, with complete loss
by 4 months [30]. However, this difference is consistent
with observations in human patients [1] and mouse
knockouts [56–59] demonstrating that common pathway
mutations are more severe than defects in fibrinogen.
One of the most intriguing findings of this study was
the synthetic lethality observed from combined loss of fib-
rinogen and Nfe2. Thrombocytes have clearly been shown
to express similar genes and function like platelets [26],
but definitive proof that they are active in preventing
hemorrhage has not been shown. The lethality in fga/;
nfe2/ mutants bolsters the belief that thrombocytes are
the functional equivalent of mammalian platelets and, to
our knowledge, these are the first in vivo data showing
that they are required for hemostasis-related survival. In
mice, fga/; nfe2/ results in lethality in the immediate
neonatal period, but zebrafish initially survive with a
steady decline until ~300 dpf. This trend is consistent with
coagulation factor knockouts that are lethal in embryonic
mice, but exhibit extended survival in zebrafish [29,30].


















Fig. 5. Treatment of fga mutants with e-aminocaproic acid rescues
the hemostatic defect. Mutant offspring were treated with 100 mM e-
aminocaproic acid at 24 hours post-fertilization (hpf). Time to occlu-
sion after endothelial injury was measured at 3 days post-fertilization
(dpf). Treated fga/ larvae (n = 110) exhibited a statistically signifi-
cant rescue compared to untreated fga/ (n = 29). P = 0.0003 by
the Mann–Whitney U-test.











hM1V c.1A>G 1 No [43]
hC55G c.221T>G 51 Yes [45]
hC64Y c.249G>A 60 Yes [45]
hY809C c.2425A>G 640 Yes [46]
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**** (P = 0.0001)
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Fig. 6. Functional analysis of human FGA variants in a fibrinogen
deficient zebrafish model. Human FGA substitutions M1V, C55G,
C64Y and Y809C were genetically engineered into the orthologous
positions of zebrafish fga cDNA in pubi-zfga-p2A-EGFP. Wild-type
(zfga) or variant cDNAs were injected into one-cell-stage embryos
from fga+/ and fga/ intercrosses and time to occlusion was
recorded after laser-induced endothelial injury, up to 120 s. Data
shown are results from fga/ larvae. Statistical significance was
determined by comparing variant (hM1V, n = 33; hC55G, n = 29;
hC64Y, n = 19; hY809C, n = 23) and zfga (n = 27) injected fga/
larvae using the Mann–Whitney U-test. Horizontal bars represent
the median time to occlusion. ns, not significant.
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species-specific factors regulating hemostatic balance,
which could be leveraged to improve our understanding
of coagulopathies. Presumably fga/; nfe2/ fish die
from hemorrhage, although given the broad timespan of
lethality and low genotypic frequency of double mutants,
definitive confirmation will require significantly larger
pedigrees.
Visible hemorrhage was noted after 1 month of age in
fga mutants, most commonly in the brain, muscle and
fins. The timing, location and extent of hemorrhage are
similar to the previous ZFN-induced fga knockout [28],
as well as our results for F10 deficiency [30]. In both
mutants, this appears to be the cause of lethality, but the
timing is significantly different, as all f10 homozygous
mutants die by 4 months of age, as opposed to 40–80%
survival at that time-point for fga mutants. Unlike mice,
there is great variability within standard zebrafish strains
[60]. Even so, genetic background is less likely to be a fac-
tor in the difference between these two strains, as the
mutant lines were produced from the same AB9TL col-
ony. It seems unlikely that differences in the genetic back-
ground of the fga and f10 mutants would cause such a
large difference in timing of lethality, suggesting that
there may be additional factors beyond the observed
hemorrhage.
The reversal of the larval hemostatic defect by e-amino-
caproic acid was surprising. Clinically, e-aminocaproic
acid is thought to stabilize clots by binding to plasmin,
preventing fibrinolysis. We have now observed rescue of
hypofibrinogenemic [29] and afibrinogenemic zebrafish
using e-aminocaproic acid, which suggests there may be
alternate mechanisms for its modulation of hemostasis.
Our previous studies of fibrinogen depletion in zebra-
fish employed antisense morpholino technology, targeting
all three fibrinogen chains, fga, fgb and fgg [31]. Individ-
ual knockdown resulted in 1–5% rates of intramuscular
and intracranial hemorrhage in 3 dpf larvae. When all
three morpholinos were co-injected, the rate increased to
nearly 20%. However, in both our TALEN-induced and
the ZFN-induced knockouts, these phenotypes were not
present. One possible explanation for this discrepancy is
that morpholino and germline targeting yield differential
phenotypic effects. There have been some reports that
suggest there is genetic compensation for germline muta-
tions, but not morpholino knockdowns [61].
Cross-regulation of coagulation factors at the mRNA
level was identified in the f10 knockout [30]. Loss of F10
resulted in statistically significant increases of fga and at3
mRNA by 75 and 100%, respectively, but no significant
effect on f2. We saw the opposite results through loss of
Fga, with decreases in f10, f2 and at3 mRNAs by ~50%.
These data suggest the possibility of a gene expression
feedback loop for the common pathway. In both mutants,
fibrin production is reduced, thus the presence or absence
of fibrinogen itself may be an important determinant of
common pathway mRNA expression. In the fga mutant
larvae, we might have expected to see a severe bleeding
phenotype, given the decrease in f10 and f2, but this
could be balanced by the decrease in at3 expression.
We have previously used zebrafish larvae for qualitative
in vivo analysis of human AT3 and F10 coagulation factor
mutations. In this work we first showed the ability to res-
cue the fga/ defect using zebrafish fga mRNA, followed
by human fibrinogen protein. Given the similarities
between human and zebrafish fibrinogen deficiencies, we
were able to use our model to discriminate the functional
consequences of human mutations, finding that M1V and
Y809C were unable to rescue the hemostatic defect. M1V
is a novel mutation that has been recently identified in
patients [51] and here we confirm it in vivo as a pathologi-
cal mutation. Surprisingly, two cysteine substitutions,
C55G (Fibrinogen La Seyne and Fibrinogen Quimper)
and C64Y (Fibrinogen Marseilles II), were able to rescue
fga/ mutants despite the fact that both positions are
highly conserved and patients with these mutations are
hypofibrinogenemic (activity levels down to 20–50% of
the lower limit of the normal range [54]). The cysteine at
position 55 has been clearly shown to be important for
disulfide formation with the Bb subunit of fibrinogen. Its
substitution results in impaired hexamer assembly, yet
continued secretion of half molecules of fibrinogen in cell
culture [62], although not in patients [54]. Hanss et al.
postulate that this is a result of overexpression in culture.
This is consistent with our data as we used the ubi pro-
moter, which drives robust expression in zebrafish
embryos and larvae [43]. The Y809C substitution was
originally an incidental finding in a pedigree with Fibrino-
gen Montreal (D515N), and segregated separately from
the affected family member [55]. Y809C is only present in
fibrinogen420, a variant comprising only ~1% of circulat-
ing fibrinogen [63], although it is 3-fold higher in fetal
plasma [64]. No functional studies had been performed
on Y809C until this report in which we demonstrate that
this variant abrogates fibrinogen function. One limitation
of these experiments is that causative mutations that
reduce human FGA expression without affecting function
would be expected to rescue the defect in thrombus for-
mation in this overexpression system.
These data expand our view of coagulation pathophysi-
ology in aquatic species. Earlier studies demonstrated sig-
nificant conservation of coagulation physiology in
zebrafish [24–26,65,66]. With the advent of genome edit-
ing, we have now expanded on this foundation and devel-
oped genetic models of coagulation disorders and used
these to identify novel functional human mutations
[29,30,66]. The phenotypes align with those seen in mam-
mals, but demonstrate a significant shift in survival. Fur-
ther understanding of the underlying biology that
explains why fish can tolerate such severe coagulation
defects, as well as in vivo analysis of clotting factor vari-
ants, may lead to novel therapeutic approaches for
patients with the associated disorders.
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